SCHEMBL360274

SCHEMBL360274

CC(C)CN1N=C(CN(C)C(=O)O)CC1=O

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
GAA P10253 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
PDE4B Q07343 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358852 0.87
SCHEMBL359796 0.86 LMNA (0.34) POLBGAAALDH1A1HPGD
SCHEMBL10080808 0.81 HTR2C (0.33) POLBGAAALDH1A1PDE4B
SCHEMBL360068 0.81 CNR2 (0.33)
SCHEMBL361729 0.80 ALDH1A1 (0.47) GAAALDH1A1
SCHEMBL359878 0.80 ALDH1A1 (0.32) GAAALDH1A1
SCHEMBL359437 0.79 ALDH1A1 (0.52) POLBGAAALDH1A1
SCHEMBL360468 0.79 KMT2A (0.38) ALDH1A1PDE4B
SCHEMBL361566 0.79 KMT2A (0.35) ALDH1A1PDE4B
SCHEMBL359249 0.78 ALDH1A1 (0.56) GAAALDH1A1HPGDPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312688-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-26 US disclosed
US-20200308119-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2020-10-01 US disclosed
US-10723703-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-07-28 US disclosed
US-20190084938-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2019-03-21 US disclosed
US-10183913-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-01-22 US disclosed
US-10087146-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-10-02 US disclosed
US-20180273489-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2018-09-27 US disclosed
US-20170217902-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2017-08-03 US disclosed
US-9663472-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-05-30 US disclosed
EP-2594559-B1 PYRAZOLE COMPOUND SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2016-02-24 EP disclosed
US-20140315971-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2014-10-23 US disclosed
US-8809383-B2 Pyrazole compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-08-19 US disclosed
US-20140031406-A1 PYRAZOLE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-30 US disclosed
US-8569353-B2 Pyrazole compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-10-29 US disclosed
EP-2594559-A1 PYRAZOLE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130116296-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2013-05-09 US disclosed
CN-103097357-A Pyrazole compound DAINIPPON SUMITOMO PHARMA CO 2013-05-08 CN disclosed
WO-2012008528-A1 PYRAZOLE COMPOUND 大日本住友製薬株式会社 (JP) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315971-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-10183913-B2 Pyrazole compound HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20170217902-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-11312688-B2 Pyrazole compound HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20130116296-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20200308119-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-10723703-B2 Pyrazole compound HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20180273489-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20190084938-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-10087146-B2 Pyrazole compound HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885
US-20140031406-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A POLB 4307/4885GAA 4858/4885ALDH1A1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.